FDA and FTC say Curalife markets CuraLin supplement with unapproved diabetes-treatment claims.
What happened
In August 2021, FDA reviewed Curalife's website and its Instagram and Facebook pages, which direct consumers to the website to buy CuraLin; FTC also reviewed the websites that month. FDA found claims and testimonials that CuraLin supports glucose levels, insulin, and management of Type 2 Diabetes. FDA concluded the product is intended as a drug, is an unapproved new drug, and lacks adequate directions for use.
What FDA found
CuraLin's website and social media claims that it supports glucose levels and manages Type 2 Diabetes show the product is intended to treat or prevent disease, making it a drug.
FD&C Act section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]CuraLin is not generally recognized as safe and effective for those uses, so it is a new drug sold without FDA approval.
FD&C Act sections 201(p), 301(d), and 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]CuraLin is misbranded because it lacks adequate directions for a layperson to use it safely for its intended disease uses.
FD&C Act section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5FTC says the company must stop claiming CuraLin can prevent, treat, or cure diabetes without competent and reliable scientific evidence, including well-controlled human clinical studies.
FTC Act, 15 U.S.C. ยง 41 et seq.
What FDA wants
FDA asks Curalife to notify it in writing within 15 working days of the specific steps taken to address the violations and prevent recurrence; if corrective actions cannot be completed in that time, state the reason and the completion date.
Who should pay attention
- dietary supplement brands making blood-sugar or diabetes claims
- retailers and online marketplaces selling CuraLin
- marketers using social media testimonials for disease claims
This is a summary. Read the original letter on fda.gov.